{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T08:49:25Z","timestamp":1649148565006},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T00:00:00Z","timestamp":1441411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s11894-015-0462-0","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T04:52:15Z","timestamp":1441428735000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature"],"prefix":"10.1007","volume":"17","author":[{"given":"Paul Y","family":"Kwo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaz B.","family":"Badshah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,5]]},"reference":[{"issue":"10","key":"462_CR1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","volume":"144","author":"GL Armstrong","year":"2006","unstructured":"Armstrong GL et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705\u201314.","journal-title":"Ann Intern Med"},{"issue":"17","key":"462_CR2","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3748\/wjg.v13.i17.2436","volume":"13","author":"MJ Alter","year":"2007","unstructured":"Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436\u201341.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"462_CR3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558\u201367.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"462_CR4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","volume":"95","author":"AK Singal","year":"2013","unstructured":"Singal AK et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95(5):755\u201360. doi: 10.1097\/TP.0b013e31827afb3a .","journal-title":"Transplantation"},{"issue":"10","key":"462_CR5","doi-asserted-by":"crossref","first-page":"868","DOI":"10.7326\/0003-4819-124-10-199605150-00002","volume":"124","author":"JYN Lau","year":"1996","unstructured":"Lau JYN et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med. 1996;124(10):868\u201376.","journal-title":"Ann Intern Med"},{"issue":"1","key":"462_CR6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2007-1007262","volume":"15","author":"J Bukh","year":"1995","unstructured":"Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 1995;15(1):41\u201363.","journal-title":"Semin Liver Dis"},{"issue":"4902","key":"462_CR7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo QL et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359\u201362.","journal-title":"Science"},{"issue":"22","key":"462_CR8","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","volume":"321","author":"GL Davis","year":"1989","unstructured":"Davis GL et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med. 1989;321(22):1501\u20136.","journal-title":"N Engl J Med"},{"issue":"22","key":"462_CR9","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","volume":"332","author":"T Poynard","year":"1995","unstructured":"Poynard T et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, Non-B hepatitis. N Engl J Med. 1995;332(22):1457\u201363.","journal-title":"N Engl J Med"},{"issue":"7053","key":"462_CR10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","volume":"436","author":"JJ Feld","year":"2005","unstructured":"Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967\u201372.","journal-title":"Nature"},{"issue":"21","key":"462_CR11","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"JG McHutchison","year":"1998","unstructured":"McHutchison JG et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339(21):1485\u201392.","journal-title":"N Engl J Med"},{"issue":"9138","key":"462_CR12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","volume":"352","author":"T Poynard","year":"1998","unstructured":"Poynard T et al. Randomised trial of interferon \u03b12b plus ribavirin for 48 weeks or for 24 weeks versus interferon \u03b12b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352(9138):1426\u201332.","journal-title":"Lancet"},{"issue":"5","key":"462_CR13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","volume":"68","author":"P Glue","year":"2000","unstructured":"Glue P et al. Hepatitis C intervention therapy group. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68(5):556\u201367.","journal-title":"Clin Pharmacol Ther"},{"issue":"9286","key":"462_CR14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958\u201365.","journal-title":"Lancet"},{"issue":"13","key":"462_CR15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975\u201382.","journal-title":"N Engl J Med"},{"issue":"6","key":"462_CR16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580\u201393.","journal-title":"N Engl J Med"},{"issue":"2","key":"462_CR17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7150\/ijms.3.69","volume":"3","author":"J Hoefs","year":"2006","unstructured":"Hoefs J, Aulakh VS. Treatment of chronic HCV infection in special populations. Int J Med Sci. 2006;3(2):69\u201374.","journal-title":"Int J Med Sci"},{"issue":"4","key":"462_CR18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","volume":"126","author":"ML Shiffman","year":"2004","unstructured":"Shiffman ML et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126(4):1015\u201323.","journal-title":"Gastroenterology"},{"issue":"6","key":"462_CR19","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.20212","volume":"39","author":"LJ Jeffers","year":"2004","unstructured":"Jeffers LJ et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39(6):1702\u20138.","journal-title":"Hepatology"},{"issue":"23","key":"462_CR20","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","volume":"292","author":"F Carrat","year":"2004","unstructured":"Carrat F et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839\u201348.","journal-title":"JAMA"},{"key":"462_CR21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-230X-3-24","volume":"3","author":"BJ Veldt","year":"2003","unstructured":"Veldt BJ et al. Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. BMC Gastroenterol. 2003;3:24.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"462_CR22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2893.2005.00682.x","volume":"13","author":"N Brau","year":"2006","unstructured":"Brau N et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2\/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*. J Viral Hepat. 2006;13(4):242\u20139.","journal-title":"J Viral Hepat"},{"issue":"12","key":"462_CR23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrd2411","volume":"6","author":"MP Manns","year":"2007","unstructured":"Manns MP et al. The way forward in HCV treatment\u2014finding the right path. Nat Rev Drug Discov. 2007;6(12):991\u20131000.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"462_CR24","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/AAC.48.12.4784-4792.2004","volume":"48","author":"K Lin","year":"2004","unstructured":"Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother. 2004;48(12):4784\u201392.","journal-title":"Antimicrob Agents Chemother"},{"issue":"25","key":"462_CR25","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405\u201316.","journal-title":"N Engl J Med"},{"issue":"25","key":"462_CR26","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417\u201328.","journal-title":"N Engl J Med"},{"issue":"11","key":"462_CR27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","volume":"365","author":"KE Sherman","year":"2011","unstructured":"Sherman KE et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014\u201324.","journal-title":"N Engl J Med"},{"issue":"14","key":"462_CR28","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","volume":"362","author":"JG McHutchison","year":"2010","unstructured":"McHutchison JG et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14):1292\u2013303.","journal-title":"N Engl J Med"},{"issue":"13","key":"462_CR29","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F et al. Boceprevir for untreated chronic HCV genotype 1 Infection. N Engl J Med. 2011;364(13):1195\u2013206.","journal-title":"N Engl J Med"},{"issue":"13","key":"462_CR30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207\u201317.","journal-title":"N Engl J Med"},{"issue":"9742","key":"462_CR31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"PY Kwo","year":"2010","unstructured":"Kwo PY et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705\u201316.","journal-title":"Lancet"},{"issue":"Supplement 1(0)","key":"462_CR32","doi-asserted-by":"crossref","first-page":"S470","DOI":"10.1016\/S0168-8278(10)61207-X","volume":"52","author":"JM Vierling","year":"2010","unstructured":"Vierling JM et al. 2016 long-term outcomes following combination treatment with boceprevir plus peg-intron\/ribavirin (P\/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1). J Hepatol. 2010;52(Supplement 1(0)):S470\u20131.","journal-title":"J Hepatol"},{"issue":"4","key":"462_CR33","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany MG et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433\u201344.","journal-title":"Hepatology"},{"issue":"8","key":"462_CR34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1517\/13543784.2012.690392","volume":"21","author":"S Tanwar","year":"2012","unstructured":"Tanwar S, Trembling PM, Dusheiko GM. TMC435 for the treatment of chronic hepatitis C. Expert Opin Investig Drugs. 2012;21(8):1193\u2013209.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"462_CR35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","volume":"61","author":"N Hayashi","year":"2014","unstructured":"Hayashi N et al. Simeprevir with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61(2):219\u201327.","journal-title":"J Hepatol"},{"issue":"9941","key":"462_CR36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403\u201313.","journal-title":"Lancet"},{"issue":"9941","key":"462_CR37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414\u201326.","journal-title":"Lancet"},{"issue":"5","key":"462_CR38","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","volume":"49","author":"N Izumi","year":"2014","unstructured":"Izumi N et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49(5):941\u201353. Evaluates the efficacy of simeprevir in patients who failed interferon-ribavirin therapy for HCV genotype 1 infection in Japan.","journal-title":"J Gastroenterol"},{"issue":"7","key":"462_CR39","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669\u201379.e3. Evaluates the efficacy of simeprevir plus interferon in patients who failed interferon-ribavirin therapy for HCV genotype 1 infection.","journal-title":"Gastroenterology"},{"issue":"14","key":"462_CR40","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1128\/JVI.00253-11","volume":"85","author":"RA Fridell","year":"2011","unstructured":"Fridell RA et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol. 2011;85(14):7312\u201320.","journal-title":"J Virol"},{"issue":"1","key":"462_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2012.09.007","volume":"170","author":"O Belda","year":"2012","unstructured":"Belda O, Targett-Adams P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res. 2012;170(1):1\u201314.","journal-title":"Virus Res"},{"issue":"1","key":"462_CR42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2011.03.026","volume":"414","author":"C Lee","year":"2011","unstructured":"Lee C et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology. 2011;414(1):10\u20138.","journal-title":"Virology"},{"issue":"5","key":"462_CR43","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1099\/0022-1317-80-5-1179","volume":"80","author":"AK Ghosh","year":"1999","unstructured":"Ghosh AK et al. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol. 1999;80(5):1179\u201383.","journal-title":"J Gen Virol"},{"issue":"31","key":"462_CR44","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1038\/sj.onc.1205589","volume":"21","author":"K-H Lan","year":"2002","unstructured":"Lan K-H et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene. 2002;21(31):4801\u201311.","journal-title":"Oncogene"},{"issue":"1","key":"462_CR45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ijc.11303","volume":"107","author":"YL Chung","year":"2003","unstructured":"Chung YL, Sheu ML, Yen SH. Hepatitis C virus NS5A as a potential viral Bcl\u20102 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer. 2003;107(1):65\u201373.","journal-title":"Int J Cancer"},{"issue":"13","key":"462_CR46","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1074\/jbc.M111392200","volume":"277","author":"Y Shirota","year":"2002","unstructured":"Shirota Y et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem. 2002;277(13):11149\u201355.","journal-title":"J Biol Chem"},{"issue":"5","key":"462_CR47","doi-asserted-by":"crossref","first-page":"e1002696","DOI":"10.1371\/journal.ppat.1002696","volume":"8","author":"TK Scheel","year":"2012","unstructured":"Scheel TK et al. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1\u20137 in infectious cell culture systems. PLoS Pathog. 2012;8(5):e1002696.","journal-title":"PLoS Pathog"},{"issue":"10","key":"462_CR48","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","volume":"110","author":"J Guedj","year":"2013","unstructured":"Guedj J et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci. 2013;110(10):3991\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"7294","key":"462_CR49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465(7294):96\u2013100.","journal-title":"Nature"},{"issue":"04","key":"462_CR50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0030-1267535","volume":"30","author":"M Poenisch","year":"2010","unstructured":"Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis. 2010;30(04):333\u201347.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"462_CR51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/187152606776056724","volume":"6","author":"U Koch","year":"2006","unstructured":"Koch U, Narjes F. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect Disord Drug Targets. 2006;6(1):31\u201341.","journal-title":"Infect Disord Drug Targets"},{"issue":"1","key":"462_CR52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hep.24342","volume":"54","author":"F Wagner","year":"2011","unstructured":"Wagner F et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology. 2011;54(1):50\u20139.","journal-title":"Hepatology"},{"issue":"8","key":"462_CR53","first-page":"614","volume":"8","author":"PL Beaulieu","year":"2007","unstructured":"Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs. 2007;8(8):614\u201334.","journal-title":"Curr Opin Investig Drugs"},{"issue":"1","key":"462_CR54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2012.02.015","volume":"57","author":"D Larrey","year":"2012","unstructured":"Larrey D et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol. 2012;57(1):39\u201346.","journal-title":"J Hepatol"},{"issue":"2","key":"462_CR55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138(2):447\u201362.","journal-title":"Gastroenterology"},{"issue":"49","key":"462_CR56","doi-asserted-by":"crossref","first-page":"20986","DOI":"10.1073\/pnas.1006370107","volume":"107","author":"KP Romano","year":"2010","unstructured":"Romano KP et al. Drug resistance against HCV NS3\/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci. 2010;107(49):20986\u201391.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"462_CR57","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","volume":"54","author":"O Lenz","year":"2010","unstructured":"Lenz O et al. In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54(5):1878\u201387.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"462_CR58","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v20.i11.2902","volume":"20","author":"S Nakamoto","year":"2014","unstructured":"Nakamoto S et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014;20(11):2902.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"462_CR59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","volume":"59","author":"J-M Pawlotsky","year":"2013","unstructured":"Pawlotsky J-M. NS5A inhibitors in the treatment of hepatitis C. J Hepatol. 2013;59(2):375\u201382.","journal-title":"J Hepatol"},{"issue":"9","key":"462_CR60","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1473-3099(12)70138-X","volume":"12","author":"S Pol","year":"2012","unstructured":"Pol S et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis. 2012;12(9):671\u20137.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"462_CR61","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/13543784.2013.826189","volume":"22","author":"DA Herbst","year":"2013","unstructured":"Herbst DA, Reddy KR. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs. 2013;22(10):1337\u201346.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"462_CR62","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54(9):3641\u201350.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"462_CR63","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1053\/j.gastro.2010.11.036","volume":"140","author":"TK Scheel","year":"2011","unstructured":"Scheel TK et al. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology. 2011;140(3):1032\u201342.","journal-title":"Gastroenterology"},{"issue":"2","key":"462_CR64","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.26660","volume":"59","author":"S Ramirez","year":"2014","unstructured":"Ramirez S et al. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology. 2014;59(2):395\u2013407.","journal-title":"Hepatology"},{"issue":"9","key":"462_CR65","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/ajg.2013.205","volume":"108","author":"H Abe","year":"2013","unstructured":"Abe H et al. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing. Am J Gastroenterol. 2013;108(9):1464\u201372.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"462_CR66","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/gutjnl-2012-302600","volume":"62","author":"N Shi","year":"2013","unstructured":"Shi N et al. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut. 2013;62(7):1055\u201361.","journal-title":"Gut"},{"issue":"10","key":"462_CR67","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/AAC.01209-12","volume":"56","author":"LA Pelosi","year":"2012","unstructured":"Pelosi LA et al. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother. 2012;56(10):5230\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supplement 2(0)","key":"462_CR68","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/S0168-8278(12)61184-2","volume":"56","author":"G Cheng","year":"2012","unstructured":"Cheng G et al. 1172 antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885. J Hepatol. 2012;56(Supplement 2(0)):S464.","journal-title":"J Hepatol"},{"issue":"1","key":"462_CR69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","volume":"57","author":"EJ Lawitz","year":"2012","unstructured":"Lawitz EJ et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol. 2012;57(1):24\u201331.","journal-title":"J Hepatol"},{"issue":"12","key":"462_CR70","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00433-06","volume":"50","author":"H Dutartre","year":"2006","unstructured":"Dutartre H et al. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2\u2032-modified nucleotide analogues. Antimicrob Agents Chemother. 2006;50(12):4161\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"462_CR71","doi-asserted-by":"crossref","unstructured":"Donaldson EF, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology, 2014.","DOI":"10.1002\/hep.27375"},{"issue":"3","key":"462_CR72","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hep.22717","volume":"49","author":"NM Kneteman","year":"2009","unstructured":"Kneteman NM et al. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti\u2010hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology. 2009;49(3):745\u201352.","journal-title":"Hepatology"},{"key":"462_CR73","doi-asserted-by":"crossref","unstructured":"Lawitz E, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. The Lancet. 383(9916):515-23. Evaluates the role of sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection.","DOI":"10.1016\/S0140-6736(13)62121-2"},{"issue":"10","key":"462_CR74","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V et al. IL28B is associated with response to chronic hepatitis C interferon-\u03b1 and ribavirin therapy. Nat Genet. 2009;41(10):1100\u20134.","journal-title":"Nat Genet"},{"issue":"4","key":"462_CR75","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","volume":"138","author":"A Rauch","year":"2010","unstructured":"Rauch A et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338\u20131345. e7.","journal-title":"Gastroenterology"},{"issue":"3","key":"462_CR76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321. Evaluates the role of combination Daclatasvir and sofosbuvir (NS5B) in patients who had chronic HCV genotype 1 infection who had not had SVR with first generation NS3\/4A protease inhibitors.","journal-title":"N Engl J Med"},{"issue":"16","key":"462_CR77","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483\u201393. Evaluates the role of combination ledipasvir (NS5A) and sofosbuvir (NS5B) in patients who had chronic HCV genotype 1 infection who had not had SVR with either interferon-based or interferon plus first generation NS3\/4A protease inhibitors.","journal-title":"N Engl J Med"},{"issue":"3","key":"462_CR78","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","volume":"55","author":"J Foucher","year":"2006","unstructured":"Foucher J et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55(3):403\u20138.","journal-title":"Gut"},{"key":"462_CR79","first-page":"1270A","volume":"60","author":"M Bourli\u00e8re","year":"2014","unstructured":"Bourli\u00e8re M, Bronowicki JP, de Ledinghen V, H\u00e9zode C, Zoulim F, Mathurin P, et al. Ledipasvir\/sofosbuvir fixed-dose combination Is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Hepatology. 2014;60:1270A. Describes the safety and efficacy of ledipasvir\/sofosbuvir in cirrhotic patients who failed prior protease-inhibitor based therapy.","journal-title":"Hepatology"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-015-0462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-015-0462-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-015-0462-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T06:23:06Z","timestamp":1567146186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-015-0462-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,5]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["462"],"URL":"https:\/\/doi.org\/10.1007\/s11894-015-0462-0","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,5]]},"article-number":"40"}}